Roche told investors on Monday that it plans to make significant cuts to both the cost and time it takes for it to develop new drugs, including its slate of experimental weight loss and diabetes medications.

Since being deemed a public health emergency in 2017, opioids are responsible for 72% of drug overdose deaths in the United States, according to the National Center for Drug Abuse Statistics.

Some oncologists are turning to GLP-1 agents to help patients shed excess pounds, with the goal of improving cancer outcomes. But data on the practice remain limited.

Semaglutide, the underlying drug marketed as Ozempic and Wegovy, works by mimicking a hormone that triggers the body to feel full. When the drug interacts with a receptor in the stomach, patients feel full sooner and for a longer period of time after eating. The drug does not cause weight loss directly – instead, it makes you want to eat less.

People with type 2 diabetes and obesity who develop kidney disease may benefit more from bariatric surgery than from GLP-1 drugs when it comes to preserving kidney function, a new study finds.

The term "Ozempic face" is not a medical term, but some use it to describe this type of appearance after weight loss. Here what's fact and fiction.

Drug companies are under fire for the high cost of Ozempic and simlar meds. A doctor said patients who can't afford it may get riskier online versions.